Pancreatic ductal adenocarcinoma is the eighth most common cancer with the lowest overall 5-year relative survival rate of any tumor type today. Expression profiling using microarrays has been widely used to identify genes associated with pancreatic cancer development. To extract maximum value from the available gene expression data, we applied a meta-analysis to search for commonly differentially expressed genes in pancreatic ductal adenocarcinoma. We obtained data sets from four different gene expression studies on pancreatic cancer. We selected a consensus set of 2984 genes measured in all four studies and applied a meta-analysis approach to evaluate the combined data. Of the genes identified as differentially expressed, several were validated using RT-PCR and immunohistochemistry. Additionally, we used a class discovery algorithm to identify a gene expression signature. Our meta-analysis revealed that the pancreatic cancer gene expression data sets shared a significant number of up-and downregulated genes, independent of the technology used. This interstudy crossvalidation approach generated a set of 568 genes that were consistently and significantly dysregulated in pancreatic cancer. Of these, 364 (64.1%) were upregulated and 204 (35.9%) were downregulated in pancreatic cancer. Only 127 (22%) were described in the published individual analyses. Functional annotation of the genes revealed that genes presumably associated with the cell adhesionmediated drug resistance pathway are frequently overexpressed in pancreatic cancer. Meta-analysis is an important tool for the identification and validation of differentially expressed genes. These could represent good candidates for novel diagnostic and therapeutic approaches to pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an important cause of malignancy-related death. In the United States, it ranks fifth among the leading causes of cancer death, accounting for approximately 30 000 deaths annually (Jemal et al., 2003) . Apart from surgery, there is no effective therapy and even resected patients usually die within 1 year postoperatively. Reasons for the poor prognosis is the occurrence of local recurrences and/or distant metastases after surgery.
Recently, various studies have applied DNA microarray technology to pancreatic cancer (for a review, see Grutzmann et al., 2004b) . These studies generated large sets of new class II cancer genes revealing dysregulation at the level of gene expression (Sager, 1997) . Given the vast amounts of data generated by gene expression profiling experiments, comparative analysis will yield more information than each experiment individually, as already demonstrated for prostate and other cancers (Rhodes et al., 2004) . Within the field of clinical investigations, meta-analysis has emerged as the gold standard for the comparison of clinical studies. It is generally accepted that only meta-analysis can circumvent the problems inherent to studies with low statistical power due to a low sample number (Collins et al., 1997) . Therefore, in this study, we performed a meta-analysis of four independent studies that applied high-density arrays for expression profiling of pancreatic cancer.
We identified and validated genes whose expression levels differed significantly between PDAC and normal pancreatic tissue, in order to generate an improved list of genes that might serve as diagnostic markers or as targets for new therapeutic approaches. Interestingly, we found an over-representation of genes associated with the cell adhesion-mediated drug resistance (CAM-DR) pathway in the set of PDAC overexpressed genes. Furthermore, we identified a set of genes that discriminate between pancreatic cancer and chronic pancreatitis.
Results
Meta-analysis techniques were originally developed to investigate the consistency of treatment effects across several small-to medium-sized clinical studies. Moreover, by including studies that were carried out in different laboratories and with different technologies, it might be possible to generalize the results.
Meta-analyses require careful selection of inclusion criteria for participating studies and sound statistical models to avoid misleading conclusions (Eysenck, 1995) . Using meta-analysis, we compared the gene expression profiles of the original data from four independent studies (Crnogorac-Jurcevic et al., 2003; Friess et al., 2003; Iacobuzio-Donahue et al., 2003b; Logsdon et al., 2003) . Therefore, a consensus set of 2984 genes that were present in each of the four studies was created. To allow sound statistical models and to avoid misleading conclusions, we were careful to select only experiments on pancreatic adenocarcinoma and normal pancreatic tissue for the analysis, since these entities were present in all data sets (Table 1) .
The beneficial effect of the meta-analysis was evident from the forest plots of gene expression data. In a number of genes, the log ratios for the data sets analysed are distributed over a wide range of values, that is for clusterin, MMP11, and ADAM9 ( Figure 1 ). In such cases, meta-analysis provides additionally statistical evidence for the assignment of differential expression.
We identified 568 differentially expressed genes: 364 (64.1%) of them were upregulated and 204 (35.9%) were downregulated in pancreatic cancer (Table 2 and Figure 2 ). Of these, only 127 (22%) were described in the published individual analyses of the four data sets.
To interpret our results in a general context, we analysed the data already published on the 568 genes using all published data sets on pancreatic cancer, including the four studies used here (Han et al., 2002; Iacobuzio-Donahue et al., 2002 CrnogoracJurcevic et al., 2003; Friess et al., 2003; Grutzmann et al., 2003; Logsdon et al., 2003; Tan et al., 2003; Nakamura et al., 2004) (Table 2) . Of the set of 568 genes, 189 were found in these 10 publications. The overexpressed genes included one gene that was published in seven studies, one gene in six, two genes in five, six in four, eight in three, and 28 in two. For 80 genes, we identified an overlap between our meta-analysis and one study. For the downregulated genes, the overlap was smaller, possibly because few data were published on downregulated genes. There were two genes that were found in four studies, two in three, and 14 in two studies. The majority of the commonly downregulated genes (54 genes) had been found in only one other study. There were only few discrepancies (24 genes) between the meta-analysis and already published data on pancreatic cancer. The small overlap of only 189 genes could be due to various factors. First, we only used PDAC, possibly allowing a more homogeneous picture of gene expression. Moreover, most authors published only part of their data.
Of the 568 genes, 62 (10.9%) were found to represent human genes already known to be involved in the tumorigenesis of PDAC, for example ADAM9, which has been found to be a prognostic factor (Grutzmann Table 2 ). Out of the 568 genes, we were able to annotate the proposed function of 241 genes (42.4%) using the KEGG database via the DAVID annotation tool. Interestingly, out of the 141 upregulated annotated genes, 13 are part of the integrin-mediated cell adhesion and another 13 of the phosphatidylinositol signaling system pathways. From the 100 downregulated annotated genes, only three and two genes are part of these two pathways, respectively. Also, within the prostaglandin and leukotriene metabolism pathway we identified six upregulated but no downregulated gene (Figure 3) .
Validation of the differential expression
Six upregulated genes and one downregulated gene were selected to have their expression validated by RT-PCR. Despite some differences in the expression level of the genes in the different cell lines, the expression of all candidate genes in all cell lines tested was as expected from the meta-analysis results (Figure 4a) . A comparison of the expression levels in eight tumors and the corresponding normal tissues revealed upregulation of ADAM9, ADAM10, EphrinB2, IRAK1, and MMP9 in many cases of PDAC, although to varying extents (Figure 4b ). The vast majority of the immunohistochemically examined samples clearly revealed cytoplasmic staining for clusterin and MMP11 and nuclear staining for mitosin ( Figure 5 and Table 3 ). Clusterin was expressed in the cytoplasm of endocrine cells, whereas only one PDAC stained weakly. Taken together, these results correspond well with the results of the meta-analysis ( Table 2 ), indicating that our approach is valid for identification of differentially expressed genes.
Identification of signature genes for chronic pancreatitis and pancreatic cancer
A predictor for the discrimination of chronic pancreatitis and PDAC from normal pancreatic tissue was identified for two data sets, which also investigated chronic pancreatitis (Table 1) . The predictor for the data set of Logsdon et al. contained 76 probe sets representing 74 genes. For the data set of Friess et al., the predictor contained 111 probe sets representing 110 genes. A comparison of the two predictor sets revealed 20 common genes in both predictors (data not shown). Validation using leave one out crossvalidation (LOO) demonstrated a correct class assignment in all cases for the data of Logsdon et al. (2003) . In the data of Friess et al. (2003) we observed that three probes were assigned to the wrong class. Validation of the identified signature led to a correct class assignment of the samples from Logsdon et al. with the predictor generated from the Friess et al. data set. Using the predictor generated from the Logsdon et al. data set on the data from Friess et al. we assigned three probes wrong (Table 4) . Also, we identified a gene signature using all 2984 genes and the data from the four different experiments. The predictor contained 346 features and predicted five out of the 69 samples used wrong (7.8%). Within the group of falsely assigned probes were two chronic pancreatitis (predicted as normal) and three PDAC samples (predicted as chronic pancreatitis). All wrongly predicted samples were from the data set of Friess et al.
Discussion
The increasing availability and maturity of DNA microarray technology has led to an explosion of cancer (a) Pancreatic cancer gene expression data sets used in the meta-analysis of microarrays (numbers in parentheses represent numbers published in the paper, which sometimes include other tumor entities besides PDAC; these were excluded from the meta-analysis). PDAC: number of pancreatic adenocarcinoma tissue samples analysed; N: number of normal pancreatic tissues; CP: number of chronic pancreatitis; Array: type of array used in the study; UG cluster: number of unique UniGene cluster represented on the used array (b) Overlap of the UniGene cluster for each data set analysed based on our results after the assignment of UniGene IDs to the probe sequences profiling studies. To extract maximum value from the accumulating mass of publicly available cancer gene expression data, methods are needed to evaluate, integrate, and intervalidate multiple data sets. Therefore, we developed and applied a statistical model for performing a meta-analysis of independent microarray data sets in pancreatic cancer. The used interstudy crossvalidation approach generated a cohort of genes that were consistently and significantly dysregulated in pancreatic cancer.
A total of 10 individual studies on gene expression in pancreatic cancer have been published so far (Han et al., 2002; Iacobuzio-Donahue et al., 2002 Crnogorac-Jurcevic et al., 2003; Friess et al., 2003; Grutzmann et al., 2003; Logsdon et al., 2003; Tan et al., 2003; Nakamura et al., 2004) . But, the concordance of these studies is rather low, with 86 genes described in at least two independent studies of 548 genes published in eight of these studies. There are several potential reasons for the low concordance of these studies, like type, histology, and number of samples (Grutzmann et al., 2004b) . Therefore, a comparison of the results of individual analyses is not sufficient to evaluate the existing plethora of gene expression data. Gene expression data often lack statistical power due to several constraints, especially low sample number, as was the case in all four studies included. This generally leads to underestimation of variances, which inflates the false-positive rate. The quality of the meta-analysis benefits from the number of single data sets analysed. We tried to obtain all gene expression data sets published for PDAC. However, we were only able to (Table 2) . Expression levels are represented by red (high) and green (low expression). Samples are depicted as in the original data sets and arrows indicate the origin of the samples Meta-analysis of expression profiling on pancreatic cancer R Grützmann et al analyse four of 10 published data sets, although according to the acknowledged scientific standards gene expression data sets have to be made publicly available. Other methods for meta-analysis of gene expression models have been suggested. For instance, Rhodes et al. (2004) developed a permutation test on p-values originating from comparisons within each individual study. However, the classical random effects metaanalysis approach applied in our study controls error rates more accurately and takes fold changes within individual studies into account. Thus, the model we applied is more conservative than that developed by Rhodes et al. Moreover, it leads to a more restrictive and perhaps more meaningful set of commonly differentially expressed genes. To support our findings, we confirmed the differential expression at the RNA (RT-PCR) or protein level (immunohistochemistry) for several genes.
It is well known that pancreatic adenocarcinoma does not respond to chemotherapy well despite the recent Meta-analysis of expression profiling on pancreatic cancer R Grützmann et al advance of adjuvant chemotherapy (Alexakis et al., 2004) . The origin of the refractory behavior of PDAC is still unknown. However, a reason might be the activation of genes that confer the cell adhesion-mediated drug resistance phenotype (Damiano et al., 1999) . The integrin-mediated cell adhesion signaling and the PI3 K signaling pathways play an important role in mediating the CAM-DR phenotype (Hazlehurst et al., 2003) . We identified a large number of genes associated with these pathways as overexpressed in PDAC by our metaanalysis (Figure 3) . Therefore, we might conclude that the CAM-DR phenotype has already developed in PDAC. Additionally, we could show by meta-analysis that essential genes for the prostaglandin and leukotriene metabolism are overexpressed in PDAC. Both cyclooxygenases (PTGS1 and PTGS2) are identified as overexpressed in PDAC by our meta-analysis (Figure 3 ). These findings underline the importance of the cyclooxygenase system for the PDAC development since it has been demonstrated that inhibition of PTGS2 leads to reduced invasiveness of pancreatic cancer cells (Ito et al., 2004) . Taken together, we were able to identify an overexpression of genes associated with CAM-DR and with increased invasiveness and metastasis in primary pancreatic adenocarcinoma. Therefore, we might conclude that these pathways are already altered in these tumors explaining the early local recurrence and metastasis in operable PDAC and the relative insensitivity to chemotherapeutics of advanced PDACs. Identification of signature genes by gene expression profiling for diagnostic and other purposes has been applied to numerous cancers (Liotta and Petricoin, 2000; Valk et al., 2004) . However, most often, these studies lack an independent confirmation of the signature genes obtained. Within the meta-analysis, we obtained two data sets that used the same microarray platform and similar sample types and numbers. We used these data sets to identify signature genes and evaluate their diagnostic potential. High sensitivity and specificity was obtained with each set of signature genes when applied to the other data set. The derivation of a classifier for discriminating between pancreatitis, PDAC, and normal tissue based on two distinct data sets indicates that gene expression data can be successfully applied to diagnose pancreatic cancer. However, the sample numbers of less than 10 per class are low. Further investigations based on larger sample sizes are therefore needed.
In summary, meta-analysis is a powerful tool for identifying the specific changes in gene expression in pancreatic cancer. Furthermore, this approach identifies relevant genes that are easily ignored in a single study and reduces the rate of 'false positives' by increasing the statistical power.
Materials and methods

Data collection
The data used in this study were publicly available (IacobuzioDonahue et al., 2003b; Logsdon et al., 2003) or were provided on request (Crnogorac-Jurcevic et al., 2003; Friess et al., 2003) . Two of the studies included used cDNA arrays and two used DNA (oligonucleotide) arrays (Table 1) . Cluster ID and gene names were assigned to all of the cDNA clones and Affymetrix probes based on UniGene Build 161. A consensus set of 2984 UniGene IDs was created. All of these genes were present in each of the four studies. The two sample groups considered in the meta-analysis were PDAC and normal pancreatic tissue (Table 1) . Therefore, samples from tumors such as ampullary carcinoma, islet cell carcinoma, or intraductal papillary mucinous tumors of the pancreas (IPMT) were excluded from the respective original data sets to achieve more homogeneous results (Table 1) . Data on chronic pancreatitis were available from Logsdon et al. (2003) and Friess et al. (2003) . These data were used to identify signature genes for chronic pancreatitis and pancreatic carcinoma. All of the available data were used except for negative values from the oligonucleotide-based studies. The expression values were base-two log-transformed. Missing data were allowed.
Meta-analysis
All statistical analyses were performed with S-PLUS Insightful (2001) (S-PLUS 6.1. guide to statistical analysis, Insightful Corporation, Seattle, WA, USA). Normalized data were used as supplied by the authors of the four studies. We applied the well-established methods for clinical studies reviewed by Whitehead and Whitehead (1991) to identify genes that all four studies revealed to be consistently up-or downregulated in PDAC versus normal pancreatic tissue. To perform this analysis, a consensus set of UniGene clusters measured in all four studies was selected. This set comprised 2984 UniGene IDs. Some of the arrays contained multiple measurements of some UniGene IDs. All of them were included as independent measure in the analysis.
The effects y i of PDAC on the genes in the consensus set in each individual study and the standard error of the effect, ffiffiffiffiffiffiffiffi w À1 i q , were estimated on the logarithmic scale using two-sided t-tests for each gene in each study separately. According to Whitehead and Whitehead, the study effect estimators follow a normal distributionŷ i $ Nðy i ; w À1 i Þ where the expected values of the individual study effects vary themselves due to laboratory and technological aspects unique to each study. Thus, expected values of study effects were assumed to be normally distributed with mean y and variance
, where Q denotes Whitehead and Whitehead's homogeneity test statistic and k the number of studies. We chose this random effects model for the meta-analysis because the test for homogeneity (H 0 : t ¼ 0) failed for nearly all genes. This assumption is a conservative extension of a fixed effects model, as it increases the variance of differential expression across all studies (Sutton et al., 2000) . With this method, an unbiased estimatorŷ for the PDAC effect across all studies is given bŷ
According to Whitehead and Whitehead, this estimator has a variance of
The statistic U for joint differential expression of a gene across all studies
follows a w 2 distribution with 1 degree of freedom under the null hypothesis, H 0 : y ¼ 0. Storey and Tibshirani's algorithm was used for stabilizing the false discovery rate at a level of 1% (Storey and Tibshirani, 2003a, b) . The putative function of the obtained differentially expressed genes was annotated using the DAVID annotation system (http://david.niaid.nih.gov/david/) and the KEGG database (http://www.genome.jp/kegg/). A heatmap of the most differentially expressed genes were constructed using dChip. For scaling purposes, the values from the experiments with Affymetrix arrays were divided by the median and logged to the basis 2.
Identification of signature genes for chronic pancreatitis and pancreatic cancer GeneCluster 2 (http://www-genome.wi. mit.edu/cancer/software/genecluster2/gc2.html) was used to identify signature genes from the data sets of Logsdon et al. and Friess et al. (Golub et al., 1999; Friess et al., 2003; Logsdon et al., 2003) . The minimal values were floored to 50 and both data sets were logged to the basis 10. Using the K-nearest neighbor (KNN) algorithm with a cosine distance function, three K-neighbors, and distance weighting 1/k, we selected a signature from both data sets using LOO. The predictor generated from one data set was then applied to the other data set. For the generation of signature genes from all four experiments expression values from all 2984 genes were used. Values derived from Affymetrix experiments, were divided by the median and logged to the basis 2. The merged data set from all four sets was loaded into GeneCluster2 and a predictor was generated using the same algorithm and validated using LOO.
Immunohistochemistry
Using a system from Beecher Instruments, Microarray Technology (Silver Springs, MD, USA), a tissue microarray (Bubendorf et al., 2001) was established from 55 wellcharacterized ductal adenocarcinomas of the pancreas (Luttges et al., 2000) including at least three different tissue cores from each carcinoma as well as three controls from normal healthy pancreatic tissues.
For immunohistochemistry, 5 mm sections were routinely prepared using sialinized slides only but no special folio (superfrost slides from Menzel Gla¨ser, Braunschweig, Germany). Antigen demasking was carefully performed using the pressure cooker method for 90 s. For staining, antibodies against clusterin (alpha-beta rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA, dilution 1 : 100), mitosin (mouse monoclonal, clone 1D8, Abcam, Cambridge, UK, dilution 1 : 50), and MMP11 (mouse monoclonal, SL3.05 Zytomed, Berlin, Germany, dilution 1 : 100) were applied. The slides were incubated for 45 min, after which the reaction was detected with a biotinylated anti-goat antibody (5 mg/ml, Vector Laboratories, Burlingame, CA, USA) and avidinbiotin-peroxidase (ABC ELITE, Vector Laboratories). Diaminobenzidine served as chromogen. Afterwards, the slides were briefly counterstained with hematoxylin. For the negative control, the primary antibody was omitted. The staining intensity was evaluated semiquantitatively. The ABC method was used for mitosin and MMP11 staining (Luttges et al., 2001) . The staining results were evaluated using a two-score system in the first round that differentiated between tumors with no staining (À) and positive staining (cytoplasmic and/or nuclear) that was clearly distinguishable from the background.
RT-PCR
RNA from four pancreatic carcinoma cell lines (Panc1, Panc89, PancTuI, and Colo357), normal pancreatic tissue and tumor tissue, was isolated using a 'Micro-to-Mini Total RNA Purification Kit' (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. Reverse transcription using random hexamers and 'Superscript' Polymerase (Invitrogen), followed by PCR amplification (581C annealing temperature, 27 cycles), was performed under standard PCR conditions in a Biometra Gradient Cycler (Biometra, Goettingen, Germany). PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The following gene-specific primers (MWG-Biotech, Ebersberg, Germany) were used for amplification: G6PD (acgtgatgcagaaccacctactg; acgacggctgcaaaagtggcg), ADAM9 (agtgctgagaggaacctgc; gggttcaatcccataactgcg), ADAM10 (gacattatgaaggattatcttac; atgataaatgacagagtgaaatg), EFNB2 (atctattggaattcctcgaactc; gggctgaattcttgaaacttg), IRAK1 (ctgtggccctggatcaac; aggccctgaatgggtctg), and MMP9 (aaccaatctcaccgacag; aaaggcgtcgtcaatcac).
